Here's your in­vi­ta­tion to this year's End­points 11 awards. Let's cel­e­brate the best of biotech to­geth­er

Over in the pub­lic mar­ket, we’re watch­ing the wheat be­ing re­morse­less­ly sep­a­rat­ed from the chaff as the biotech sec­tor went from every­one’s dar­ling to the or­phan child of Wall Street. That was in­evitable. But while there’s been a knock-on ef­fect in the ven­ture in­vest­ing side, we’re see­ing clear ev­i­dence that big play­ers are stick­ing with their game plan: Ma­jor tech­no­log­i­cal break­throughs are open­ing doors to biotech star­tups that didn’t ex­ist five years ago — and the so­phis­ti­cat­ed in­vestors don’t want to miss out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.